NEWAVE PHARMACEUTICAL INC.
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Private
- Employees
- -
- Market Cap
- -
- Website
- http://www.newavepharma.com/
Study of Oral Administration of LP-168 in Patients With Relapsed or Refractory B-cell Malignancies.
Phase 1
Recruiting
- Conditions
- Hairy Cell LeukemiaWaldenstrom MacroglobulinemiaCLL/SLLMantle Cell LymphomaMarginal Zone LymphomaFollicular LymphomaDiffuse Large B Cell Lymphoma
- Interventions
- First Posted Date
- 2021-03-01
- Last Posted Date
- 2023-11-14
- Lead Sponsor
- Newave Pharmaceutical Inc
- Target Recruit Count
- 60
- Registration Number
- NCT04775745
- Locations
- 🇺🇸
Duke Univerisity, Durham, North Carolina, United States
🇺🇸Ohio State University, Columbus, Ohio, United States
🇺🇸Huntsman Cancer Institute, University of Utah, Salt Lake City, Utah, United States
Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL.
Phase 1
Recruiting
- Conditions
- Richter TransformationT-cell-prolymphocytic LeukemiaMyelodysplastic/Myeloproliferative NeoplasmSmall Lymphocytic LymphomaMyelodysplastic Neoplasm in Blast PhaseNon Hodgkin LymphomaMultiple MyelomaAcute Lymphocytic LeukemiaAcute Myeloid LeukemiaMyeodysplastic Syndrome
- Interventions
- First Posted Date
- 2021-02-25
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Newave Pharmaceutical Inc
- Target Recruit Count
- 100
- Registration Number
- NCT04771572
- Locations
- 🇺🇸
University of Chicago, Chicago, Illinois, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸MD Anderson Cancer Center, Houston, Texas, United States
Dose-Escalation Study of Oral Administration of LP-108 as Monotherapy and in Combination With Azacitidine in Patients With Relapsed or Refractory MDS, CMML, or AML
Phase 1
Active, not recruiting
- Conditions
- AML/MDSCMMLRelapseRefractory Acute Lymphoblastic LeukemiaRelapse LeukemiaRelapsed Adult AML
- Interventions
- First Posted Date
- 2019-10-25
- Last Posted Date
- 2024-04-24
- Lead Sponsor
- Newave Pharmaceutical Inc
- Target Recruit Count
- 36
- Registration Number
- NCT04139434
- Locations
- 🇪🇸
Hospital San Pedro de Alcántara, Cáceres, Spain
🇪🇸Instituto de Investigación Sanitaria La Fe, Valencia, Spain
🇺🇸University of Cincinnati, Cincinnati, Ohio, United States
© Copyright 2025. All Rights Reserved by MedPath